Health Care & Life Sciences » Biotechnology | Capricor Therapeutics Inc.

Capricor Therapeutics Inc.

Capricor Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
Market Cap
$12.76 M
Shares Outstanding
3.47 M
Public Float
19.96 M


8840 Wilshire Boulevard
Beverly Hills California 90211
United States
Employees -
Updated 07/08/2019
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on November 20, 2013 and is headquartered in Beverly Hills, CA.


View All

Linda Marbán
President, Chief Executive Officer & Director
Frank Litvack
Executive Chairman